I wonder if everyone buying $CLDN at this price realizes it could technically be worth $0 next month if the trial is a complete failure?
The Times: CTI BioPharma (CTIC) may announce positive news on a drug or a obligatory bid.
BIOC market cap is over $100 million after the dilution. This is why it only moved .40 on 12 million shares. The warrant holders? Are converting from $1.56 & selling to you. This is a $1.50 stock.
Let's see...they said 401 data mid year & more at ASH. 501 data in Nov. 801 IND this year & that is why they raised the extra cash. My thoughts....cash rich biotech with no debt. Several catalysts into mid & end of year. I like this stock here and I own it around $14.
Says expect data soon, many data points in 2015. Should benefit from January effect of small caps.
BLRX ready to show it's strategy.....one that PFE & LLY are following......I am impressed:
December 12, 2014
BioLineRx to host Investor/Analyst Breakfast in New York from 8am to 10am EST on December 12, 2014 to present the Company's 2015 clinical development strategy for BL-8040 (AML and other hematological indications)
Keynote presentation to be given by Dr. Jorge Cortes, Distinguished Professor of Leukemia Research at the MD Anderson Cancer Center in Houston, Texas
Convene Conference Center
730 Third Avenue (between 45th and 46th Streets)
New York, NY 10017
Not only are the presenting data at ASH in same indications that PFE & LLY are targeting, but read this note from Roth:
10 Nov 12:00 [BLRX] Roth Capital reiterates Buy rating, price target $8 - Firm believes BioLine is on the verge of significant news flow, which they believe will provide further boost to its U.S. visibility. While the company is not vocal on the topic, firm believes the upcoming data catalysts across the pipeline will be instrumental in potential partnering discussions. The company's broad pipeline of products also allows for spreading out of the underlying risk to valuation.
Finally the bottom is reached.